pyrroles has been researched along with Itching in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, WJ; Shim, WS | 1 |
| Agner, T; Bauer, A; Ehst, B; Korn, S; Resen, K; Schliemann, S; Shi, VY; Thyssen, JP; Tillmann, S; Worm, M | 1 |
| Ju, T; Labib, A; Vander Does, A; Yosipovitch, G | 1 |
| Amano, W; Egawa, G; Hamada, Y; Hayashi, M; Honda, T; Ishida, Y; Kabashima, K; Konishi, N; Matsushita, M; Nakashima, C; Otsuka, A; Tanimoto, A; Usui, K; Wada, M; Yamamoto, Y | 1 |
| Igarashi, A; Nagata, T; Nakagawa, H; Nemoto, O | 1 |
| Bushmakin, AG; Cappelleri, JC; Luger, T; Mamolo, C; Ständer, S; Tallman, AM; Yosipovitch, G; Zielinski, MA | 1 |
| Nagata, T; Nakagawa, H; Nemoto, O; Ninomiya, N; Yamada, H | 1 |
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, C; Stewart, M | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, CM | 1 |
| Bäumer, W; Cook, E; Ehling, S; Fukuyama, T | 1 |
| Bäumer, W; Fukuyama, T; Qi, Y; Tschernig, T; Volmer, DA | 1 |
| Augustin, M; Buonanno, M; de la Cruz, C; Feldman, SR; Gooderham, M; Kaur, M; Lan, S; Mallbris, L; Mamolo, C; Tatulych, S; Thaçi, D; Valdez, H | 1 |
| Gershovich, OE; Lyman, AE | 1 |
| Corre, KA; Rothstein, RJ | 1 |
| Reimer, GW | 1 |
| Cooper, JW; McCall, CY | 1 |
| Paulus, HE; Restivo, C | 1 |
6 trial(s) available for pyrroles and Itching
| Article | Year |
|---|---|
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Topics: Adult; Dermatitis, Atopic; Double-Blind Method; Eczema; Emollients; Humans; Immunoglobulin A; Janus Kinase Inhibitors; Pain; Pruritus; Pyrroles; Severity of Illness Index; Treatment Outcome | 2022 |
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Dermatitis, Atopic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Topics: Administration, Cutaneous; Adult; Dermatitis, Atopic; Dermatitis, Phototoxic; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Ointments; Patch Tests; Placebos; Pruritus; Pyrroles; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2018 |
The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome | 2015 |
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Topics: Double-Blind Method; Humans; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2015 |
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Topics: Adult; Female; Humans; Male; Middle Aged; Pain; Patient Satisfaction; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2016 |
12 other study(ies) available for pyrroles and Itching
| Article | Year |
|---|---|
Cutaneous Neuroimmune Interactions of TSLP and TRPV4 Play Pivotal Roles in Dry Skin-Induced Pruritus.
Topics: Animals; Cells, Cultured; Cytokines; Ganglia, Spinal; Humans; Keratinocytes; Male; Mast Cells; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Morpholines; Neuroimmunomodulation; Neurons; Pruritus; Pyrroles; Skin; Thymic Stromal Lymphopoietin; TRPV Cation Channels | 2021 |
Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series.
Topics: Dermatitis; Humans; Janus Kinases; Piperidines; Pruritus; Pyrimidines; Pyrroles | 2022 |
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Topics: Administration, Cutaneous; Animals; Antipruritics; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Janus Kinase Inhibitors; Male; Mice; Pruritus; Pyrroles; Skin | 2020 |
Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Topics: Antipruritics; Clinical Trials, Phase III as Topic; Humans; Piperidines; Predictive Value of Tests; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Antipruritics; Cytokines; Dermatitis, Allergic Contact; Disease Models, Animal; Female; Inflammation; Janus Kinases; Lymph Nodes; Mice; Mice, Inbred BALB C; Piperidines; Pruritus; Pyrimidines; Pyrroles; Skin; Sulfonamides | 2015 |
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Topics: Administration, Oral; Aggression; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Behavior, Animal; Brain; Dermatitis, Atopic; Disease Models, Animal; Female; Janus Kinases; Male; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Pyrroles; Stress, Psychological; Sulfonamides; Toluene 2,4-Diisocyanate | 2015 |
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.
Topics: Administration, Oral; Aged; Alanine Transaminase; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Liver Function Tests; Pruritus; Pyrroles | 2004 |
Anaphylactic reaction to zomepirac.
Topics: Analgesics; Anaphylaxis; Anti-Inflammatory Agents; Blood Pressure; Epinephrine; Female; Humans; Hypersensitivity, Immediate; Middle Aged; Pruritus; Pyrroles; Rhinitis, Allergic, Seasonal; Seizures; Tolmetin | 1982 |
An unusual allergic reaction.
Topics: Erythema; Female; Humans; Pruritus; Pyrroles; Tolmetin | 1981 |
Tolmetin anaphylactoid reaction.
Topics: Anaphylaxis; Drug Hypersensitivity; Humans; Male; Middle Aged; Neurodermatitis; Pruritus; Pyrroles; Tolmetin; Urticaria | 1980 |
Anaphylaxis from tolmetin.
Topics: Adult; Anaphylaxis; Arthritis, Rheumatoid; Female; Humans; Pruritus; Pyrroles; Tolmetin | 1978 |